Walleye Capital LLC Purchases Shares of 82,199 Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Walleye Capital LLC invested approximately $1.18 million in Centessa Pharmaceuticals by acquiring 82,199 shares, representing a 0.06% ownership stake as of its latest SEC filing.
• Multiple large investors have significantly increased their stakes in Centessa Pharmaceuticals, with Barclays PLC boosting its holdings by 1,414.9% last quarter.
• Analysts have set a consensus target price of $31.50 for Centessa Pharmaceuticals, with several firms giving it a "buy" rating, while Wall Street Zen recently downgraded it to "sell."

Walleye Capital LLC bought a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 82,199 shares of the company's stock, valued at approximately $1,182,000. Walleye Capital LLC owned approximately 0.06% of Centessa Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of CNTA. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd increased its stake in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals in the first quarter worth about $47,000. Barclays PLC lifted its stake in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in Centessa Pharmaceuticals during the fourth quarter valued at approximately $162,000. Institutional investors and hedge funds own 82.01% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on CNTA. Needham & Company LLC initiated coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Wall Street Zen cut shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on Centessa Pharmaceuticals in a report on Wednesday. They issued an "overweight" rating and a $31.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and twelve have given a Buy rating to the stock. According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $31.45.

Insider Activity

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 12,000 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total value of $168,240.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at approximately $1,477,511.72. This trade represents a 10.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Mario Alberto Accardi sold 15,000 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $14.00, for a total transaction of $210,000.00. Following the transaction, the insider directly owned 216,485 shares in the company, valued at approximately $3,030,790. This represents a 6.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 171,322 shares of company stock worth $2,472,814 in the last ninety days. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Trading Down 0.3%

Shares of Centessa Pharmaceuticals stock traded down $0.05 during trading on Thursday, reaching $15.86. 562,293 shares of the company were exchanged, compared to its average volume of 971,007. The business has a 50-day moving average price of $15.88 and a 200-day moving average price of $14.47. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -8.86 and a beta of 1.47. The company has a quick ratio of 10.12, a current ratio of 10.11 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Sell-side analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.